Head, In Vitro Antibody Discovery & AI-Driven Platforms

Boehringer Ingelheim Pharmaceuticals, Inc.; Ridgefield (CT); On-site; USD 141,000 - 250,000; Full time

Benefits offered by this job

Medical, dental, and vision benefits

Relocation assistance

Paid time off

Job summary

Boehringer Ingelheim is seeking a Senior Principal Scientist or Principal Scientist to lead the in vitro antibody discovery team in Ridgefield, CT. You will define and execute innovative in vitro strategies for phage and yeast display campaigns that drive therapeutic lead identification.

The role emphasizes automation, high-throughput screening, NGS, and AI/ML enabled approaches to enhance hit quality, accelerate timelines, and expand sequence diversity, while mentoring staff and contributing to

Qualifications

• Requires PhD and 5–7 years industry experience in a related field.
• Experience leading employees, projects and leaders is required.
• Deep expertise in phage, yeast, or mammalian display technologies.
• Strong background in NGS analysis, AI/ML based sequence or structure modeling.

Responsibilities

• Lead a team generating novel antibodies using phage and yeast display, ML-guided library evolution, and in silico discovery tools.
• Design high diversity antibody libraries and perform affinity maturation.
• Implement in vitro discovery strategies with panning, HTS and NGS-guided hit prioritization with AI-accelerated workflows.
• Mentor junior staff, publish and present findings, and collaborate across functions.

Skills

Leadership

Project management

Mentoring

Communication

Education

PhD

Tools

Geneious

PipeBio

Job description

Boehringer Ingelheim is seeking a Senior Principal Scientist or Principal Scientist to lead the in vitro antibody discovery team in Ridgefield, CT. You will define and execute innovative in vitro strategies for phage and yeast display campaigns that drive therapeutic lead identification.

The role emphasizes automation, high-throughput screening, NGS, and AI/ML enabled approaches to enhance hit quality, accelerate timelines, and expand sequence diversity, while mentoring staff and contributing to